As has been shown, trace element supplementation by zinc, e.g., in the form of zinc oxide (ZnO), can significantly influence the anxiety level. We investigated the effects of ZnO in the form of nanoparticles (NPs) in comparison with conventional ZnO (cZnO) in an animal model of anxiety. Adult male Wistar rats were divided into seven groups, control (receiving 0.9% saline) and six groups receiving 5, 10, and 20 mg/kg ZnO NPs and 5, 10, and 20 mg/kg cZnO. All drugs dispersed in 0.9% saline were injected i.p.; 30 min later, the anxiety level was estimated according to the results of the elevated plus maze test. ZnO NPs (5 mg/kg) and cZnO (10 and 20 mg/kg) significantly increased the normalized values of time spent in open arms (open arm time, OAT, %) in comparison with the control group (P < 0.05). This is indicative of the anxiolytic effects of these components; in addition, 20 mg/kg ZnO NPs reduced the intensity of locomotor activity (P < 0.05). The serum zinc concentration was increased manifold by anxiolytic doses of the components. All doses increased serum pH to 8.05-8.10 and kept this index constant for 24 h. These results indicate that the anxiolytic effect of ZnO NPs is much more intense than that of conventional ZnO, but the introduction of ZnO NP as a new drug for the treatment of anxiety disorders needs further investigations.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
R. C. Kessler, W. T. Chiu, O. Demler, and E. E. Walters, “Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication,” Arch. Gen. Psychiat., 62, No. 6, 617–627 (2005).
T. E. Moffitt, H. Harrington, A. Caspi, et al., “Depression and generalized anxiety disorder: cumulative and sequential comorbidity in a birth cohort followed prospectively to age 32 years,” Arch. Gen. Psychiat., 64, No. 6, 651–660 (2007).
A. Takeda, “Movement of zinc and its functional significance in the brain,” Brain. Res. Rev., 34, No. 3, 137–148 (2000).
N. L. Harrison and S. J. Gibbons, “Zn2+: an endogenous modulator of ligand- and voltage-gated ion channels,” Neuropharmacology, 33, 935–952 (1994).
J. Magistretti, L. Castelli, V. Taglietti, and F. Tanzi, “Dual effect of Zn2+ on multiple types of voltage-dependent Ca2+ currents in rat palaeocortical neurons,” Neuroscience, 117, No. 2, 249–264 (2003).
T. G. Smart, X. Xie, and B. J. Krishek, “Modulation of inhibitory and excitatory amino acid receptor ion channels by zinc,” Prog. Neurobiol., 42, 393–441 (1994).
A. S. Prasad, “Discovery of human zinc deficiency: 50 years later,” J. Trace. Elem. Med. Biol., 26, 66–69 (2012).
N. M Tassabehji, R. S. Corniola, A. Alshingiti, and C. W. Levenson, “Zinc deficiency induces depressionlike symptoms in adult rats,” Physiol. Behav., 95, No. 3, 365–369 (2008).
N. Whittle, G. Lubec, and N. Singewald, “Zinc deficiency induces enhanced depression-like behavior and altered limbic activation reversed by antidepressant treatment in mice,” Amino Acids, 36, No. 1, 147–158 (2009).
S. Sobhanirad, R. Valizade, A. Moghimi, and A. Tahmasebi, “Evaluation of the anxiolytic effects of zinc supplemented diet in the elevated plus-maze test,” Res. J. Biol. Sci., 3, No. 9, 964–967 (2008).
H. M. Edwards and D. H. Baker, “Bioavailability of zinc in several sources of zinc oxide, zinc sulfate, and zinc metal,” J. Anim. Sci., 77, No. 10, 2730–2735 (1999).
M. V. Do Carmo E Sб, L. E. Pezzato, M. M. Barros, and N/ P. P. De Magalhгes Padilha, “Relative bioavailability of zinc in supplemental inorganic and organic sources for Nile tilapia, Oreochromisniloticus fingerlings,” Aquacult. Nutr., 11, No. 4, 273–281 (2005).
C. M. Sayes, K. L. Reed, and D. B. Warheit, “Assessing toxicity of fine and nanoparticles: comparing in vitro measurements to in vivo pulmonary toxicity profiles,” Toxicol. Sci., 97, No. 1, 163–180 (2007).
A. Nel, T. Xia, L. Mдdler, and N. Li, “Toxic potential of materials at the nanolevel,” Science, 311, No. 5761, 622–627 (2006).
T. Jin, D. Sun, J. Y. Su, et al., “Antimicrobial efficacy of zinc oxide quantum dots against Listeria monocytogenes, Salmonella enteritidis, and Escherichia coli O157:H7,” J. Food. Sci., 74, No. 1, 46–52 (2009).
L. Yan, F. Zhao, S. J. Li, et al., “Low-toxic and safe nanomaterials by surface-chemical design, carbon nanotubes, fullerenes, metallofullerenes and graphenes,” Nanoscale, 3, No. 2, 362–382 (2011).
J. W. Rasmussen, E. Martinez, P. Louka, and D. G. Wingett, “Zinc oxide nanoparticles for selective destruction of tumor cells and potential for drug delivery applications,” Expert. Opin. Drug. Deliv., 7, No. 9, 1063–1077 (2010).
H. J. Wang, A. C. Growcock, T. H. Tang, et al., “Zinc oxide nanoparticle disruption of store-operated calcium entry in a muscarinic receptor signaling pathway,” Toxicol. In Vitro, 24, No. 7, 1953–1961 (2010).
A. O. Rosa, J. Lin, J. B. Calixto, et al., “Involvement of NMDA receptors and L-arginine-nitric oxide pathway in the antidepressant-like effects of zinc in mice,” Behav. Brain. Res., 144, 87–93 (2003).
M. R. Zarrindast, Sahand Babapoor-Farrokhran, Savalan Babapoor-Farrokhran, and A. Rezayof, “Involvement of opioidergic system of the ventral hippocampus, the nucleus accumbens or the central amygdala in anxietyrelated behavior,” Life. Sci., 82, 1175–1181 (2008).
M. Mard-Soltani, M. Kesmati, L. Khajehpour, et al., “Interaction between anxiolytic effect of testosterone and b-1 adrenoceptors of basolateral amygdala,” Int. J. Pharmacol., 8, No. 5, 344–354 (2012).
G. Sonavane, K. Tomoda, and K. Makino, “Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size,” Colloids. Surf., B, Biointerfaces, 66, 274–280 (2008).
B. D. Chithrani, A. A. Ghazani, and W. C. W. Chan, “Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells,” Nano Lett., 4, 662–668 (2006).
S. Arora, J. M. Rajwade, and K. M. Paknikar, “Nanotoxicology and in vitro studies: The need of the hour,” Toxicol. Appl. Pharmacol., 258, No. 2, 151–165 (2012).
X. Peng, S. Palma, N. S. Fisher, and S. S. Wong, “Effect of morphology of ZnO nanostructures on their toxicity to marine algae,” Aquat. Toxicol., 102, Nos. 3/4, 186–196 (2011).
P. Decuzzi, F. Causa, M. Ferrari, and P. A. Netti, “The effective dispersion of nanovectors within the tumor microvasculature,” Ann. Biomed. Eng., 34, No. 4, 633–641 (2006).
A. Takeda and H. Tamano, “Insight into zinc signaling from dietary zinc deficiency,” Brain. Res. Rev., 62, No. 1, 33–44 (2009).
P. Paoletti, A. M. Vergnano, B. Barbour, and M. Casado, “Zinc at glutamatergic synapses,” Neuroscience, 158, No. 1, 126–136 (2009).
V. Bergink, H. J. G. M. Van Megen, and H. G. M. Westenberg, “Glutamate and anxiety,” Eur. Neuropsychopharmacol., 14, 175–183 (2004).
C. M. Padovan, E. A. Del Bel, and F. S. Guimaraes, “Behavioral effects in the elevated plus maze of an NMDA antagonist injected into the dorsal hippocampus: influence of restraint stress,” Pharmacol. Biochem. Behav., 67, No. 2, 325–330 (2000).
J. Y. Koh and D. W. Choi, “Zinc toxicity on cultured cortical neurons: Involvement of N-methyl-D-aspartate receptors,” Neuroscience, 60, No. 4, 1049–1057 (1994).
Y. V. Li, C. J. Hough, and J. M. Sarvey, “Do we need zinc to think?” Sci. STKE, 182, 19 (2003).
M. Rezvanfard, M. R. Zarrindast, and P. Bina, “Role of ventral hippocampal GABA(A) and NMDA receptors in the anxiolytic effect of carbamazepine in rats using the elevated plus maze test,” Pharmacology, 84, No. 6, 356–366 (2009).
A. Takeda, M. Hirate, H. Tamano, and N. Oku, “Release of glutamate and GABA in the hippocampus under zinc deficiency,” J. Neurosci. Res., 72, 537–542 (2003).
A. Takeda, A. Minami, Y. Seki, and N. Oku, “Differential effects of zinc on glutamatergic and GABAergic neurotransmitter systems in the hippocampus,” J. Neurosci. Res., 75, 225–229 (2004).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Torabi, M., Kesmati, M., Harooni, H.E. et al. Different Efficacy of Nanoparticle and Conventional ZnO in an Animal Model of Anxiety. Neurophysiology 45, 299–305 (2013). https://doi.org/10.1007/s11062-013-9372-7
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11062-013-9372-7